Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Our study aimed to investigate the effect of interferon beta 1a on the clinical and immunological parameters in Egyptian relapse-remitting multiple sclerosis patients
Until recently, relapsing-remitting multiple sclerosis (RRMS) was considered a homogeneous form of multiple sclerosis (MS). Variability both in the immunopathology of active demyelinating lesions in MS and in response to immunomodulatory treatments has demonstrated that RRMS is a heterogeneous form of MS. An overwhelming number of trials have supported the use of interferon-β (IFN-β) as a first-line immunomodulatory treatment in RRMS. Approximately 30% of IFN-β treated RRMS patients are non-responders (NR) to treatment. Despite vast clinical experience in the use of IFN-β, its mechanisms of action have not been fully clarified. Interleukin-17 (IL-17) is a proinflammatory cytokine that is secreted by a lineage of T cells named Th17 cells. The Th17 chemokine pathways are essential for the development of central nervous system (CNS) autoimmune diseases such as MS. A high IL-17 concentration in the serum. of people with RRMS is associated with nonresponse to IFN-β therapy. Some animal and human studies have shown that IFN-β inhibits the activity of Th17 cells.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 | RRMS patients who received Interferon beta 1a and have normal weight |
| |
| Group 2 | RRMS patients who received Interferon beta 1a and have are obese |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Blood sample collection | Other | 5 ml of blood samples were withdrawn from RRMS patients |
|
| Measure | Description | Time Frame |
|---|---|---|
| Correlation between IL17 levels and patients' response to interferon beta 1a as measured by ELISA | Anti-inflammatory and disease activity biomarkers | Patients were treated with INF B 1a for at least 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Correlation between IL 22 levels and patients' response to interferon beta 1a, measured by ELISA | Anti-inflammatory and disease activity biomarkers | Patients were treated with INF B 1a for at least 6 months |
| Correlation between Expanded Disability Status Scale and patients' response to interferon beta 1a |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Egyptian Relapsing-Remitting Multiple Sclerosis Patients
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Nasser Institute for Research and Treatment | Cairo | 1053 | Egypt |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 19446274 | Background | Rudick RA, Polman CH. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol. 2009 Jun;8(6):545-59. doi: 10.1016/S1474-4422(09)70082-1. | |
| 10852536 | Background | Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000 Jun;47(6):707-17. doi: 10.1002/1531-8249(200006)47:63.0.co;2-q. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood samples
Determination disability level (0 - 6), The lowest value means that it is best outcome and the highest value is the worst outcome. |
| Patients were treated with INF B 1a for at least 6 months |
| Correlation between malondialdehyde levels and patients' response to interferon beta 1a | oxidative stress biomarkers | Patients were treated with INF B 1a for at least 6 months |
| Correlation between MRI load and Patients' response to interferon beta 1a | Determination of T2 lesions | Patients were treated with INF B 1a for at least 6 months |
| Correlation between body mass index and patients' response to interferon beta 1 a | Body weight measurement | Patients were treated with INF B 1a for at least 6 months |
| 20439848 | Background | Hesse D, Krakauer M, Lund H, Sondergaard HB, Langkilde A, Ryder LP, Sorensen PS, Sellebjerg F. Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response. Neurology. 2010 May 4;74(18):1455-62. doi: 10.1212/WNL.0b013e3181dc1a94. |
| 21530402 | Background | Axtell RC, Raman C, Steinman L. Interferon-beta exacerbates Th17-mediated inflammatory disease. Trends Immunol. 2011 Jun;32(6):272-7. doi: 10.1016/j.it.2011.03.008. Epub 2011 Apr 29. |
| 19933767 | Background | Brucklacher-Waldert V, Stuerner K, Kolster M, Wolthausen J, Tolosa E. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain. 2009 Dec;132(Pt 12):3329-41. doi: 10.1093/brain/awp289. |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |